NCT03268954 2025-10-29
PANTHER
Takeda
Phase 3 Completed
Clinical Trials
7 trialsNCT03813147 2025-04-13
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1 Completed
NCT03814005 2024-09-05
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
Phase 1 Completed
NCT02782468 2023-11-03
A Study of Pevonedistat in Adult East Asian Participants
Takeda
Phase 1 Completed
NCT04712942 2023-08-21
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
University of Leipzig
Phase 2 Completed
NCT02610777 2022-09-19
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Takeda
Phase 2 Completed
NCT00911066 2013-12-05
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Millennium Pharmaceuticals, Inc.
Phase 1 Completed